RU2008112144A - Композиции, включающие слаборастворимые в воде фармацевтические вещества и противомикробные вещества - Google Patents
Композиции, включающие слаборастворимые в воде фармацевтические вещества и противомикробные вещества Download PDFInfo
- Publication number
- RU2008112144A RU2008112144A RU2008112144/15A RU2008112144A RU2008112144A RU 2008112144 A RU2008112144 A RU 2008112144A RU 2008112144/15 A RU2008112144/15 A RU 2008112144/15A RU 2008112144 A RU2008112144 A RU 2008112144A RU 2008112144 A RU2008112144 A RU 2008112144A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- composition according
- substance
- albumin
- soluble pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/701—Integrated with dissimilar structures on a common substrate
- Y10S977/702—Integrated with dissimilar structures on a common substrate having biological material component
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/701—Integrated with dissimilar structures on a common substrate
- Y10S977/702—Integrated with dissimilar structures on a common substrate having biological material component
- Y10S977/705—Protein or peptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Abstract
1. Композиция, содержащая слабо растворимое в воде фармацевтическое вещество, белок-носитель и противомикробное вещество, отличное от дефероксамина, где значимый рост микробов в композиции подавлен. ! 2. Композиция по п.1, где белком-носителем является альбумин. ! 3. Композиция по п.2, где весовое отношение альбумина к слабо растворимому в воде фармацевтическому веществу в композиции составляет приблизительно 18:1 или менее. ! 4. Композиция по п.1, где композиция содержит наночастицы слаборастворимых в воде фармацевтических веществ с белком-носителем. ! 5. Композиция по п.4, где белком-носителем является альбумин. ! 6. Композиция по п.5, где весовое отношение альбумина к слабо растворимому в воде фармацевтическому веществу в композиции составляет приблизительно 18:1 или менее. ! 7. Композиция по п.4, где наночастицы в композиции имеют средний диаметр не более чем приблизительно 200 нм. ! 8. Композиция по п.7, где композиция стерилизована фильтрованием. ! 9. Композиция по п.1, где композиция является водной суспензией слабо растворимого в воде фармацевтического вещества в концентрации от приблизительно 0,1 до 20 мг/мл. ! 10. Композиция по п.1, где композиция является лиофилизированной композицией, которую можно восстановить в водную суспензию слабо растворимого в воде фармацевтического вещества в концентрации от приблизительно 0,1 до 20 мг/мл. ! 11. Композиция по п.1, где композиция пригодна для парентерального введения. ! 12. Композиция по п.1, где композиция в основном не содержит Cremophor®. ! 13. Композиция по любому из пп.1-12, где количество противомикробного вещества в композиции не вызывает токсического эффекта, когда композицию вводят индивидуум
Claims (34)
1. Композиция, содержащая слабо растворимое в воде фармацевтическое вещество, белок-носитель и противомикробное вещество, отличное от дефероксамина, где значимый рост микробов в композиции подавлен.
2. Композиция по п.1, где белком-носителем является альбумин.
3. Композиция по п.2, где весовое отношение альбумина к слабо растворимому в воде фармацевтическому веществу в композиции составляет приблизительно 18:1 или менее.
4. Композиция по п.1, где композиция содержит наночастицы слаборастворимых в воде фармацевтических веществ с белком-носителем.
5. Композиция по п.4, где белком-носителем является альбумин.
6. Композиция по п.5, где весовое отношение альбумина к слабо растворимому в воде фармацевтическому веществу в композиции составляет приблизительно 18:1 или менее.
7. Композиция по п.4, где наночастицы в композиции имеют средний диаметр не более чем приблизительно 200 нм.
8. Композиция по п.7, где композиция стерилизована фильтрованием.
9. Композиция по п.1, где композиция является водной суспензией слабо растворимого в воде фармацевтического вещества в концентрации от приблизительно 0,1 до 20 мг/мл.
10. Композиция по п.1, где композиция является лиофилизированной композицией, которую можно восстановить в водную суспензию слабо растворимого в воде фармацевтического вещества в концентрации от приблизительно 0,1 до 20 мг/мл.
11. Композиция по п.1, где композиция пригодна для парентерального введения.
12. Композиция по п.1, где композиция в основном не содержит Cremophor®.
13. Композиция по любому из пп.1-12, где количество противомикробного вещества в композиции не вызывает токсического эффекта, когда композицию вводят индивидууму.
14. Композиция по любому из пп.1-12, где противомикробным веществом является комплексообразующее вещество.
15. Композиция по п.14, где комплексообразующее вещество выбрано из группы, состоящей из эдетата, цитрата, пентетата, трометамина, их производных и их смесей.
16. Композиция по п.15, где комплексообразующее вещество содержит цитрат и эдетат.
17. Композиция по п.16, где комплексообразующее вещество содержит 200 мМ цитрата и ЭДТА.
18. Композиция по любому из пп.1-12, где противомикробным веществом является некомплексообразующее вещество.
19. Композиция по п.18, где некомплексообразующее вещество выбрано из группы, состоящей из сульфитов, бензойной кислоты, бензилового спирта, хлорбутанола, парабена, их производных и их смесей.
20. Композиция по любому из пп.1-12, где слабо растворимое фармакологическое вещество выбрано из группы, состоящей из паклитаксела, доцетаксела, ортатаксела или других таксанов, гельданамицина, 17-аллиламиногельданамицина, димера тиоколхицина, рапамицина, циклоспорина, эпотилона, радицикола и комбретастина.
21. Композиция по п.20, где слаборастворимым фармакологическим веществом является таксан или его производное.
22. Композиция по п.21, где слабо растворимым фармакологическим веществом является паклитаксел.
23. Композиция по п.17, где слабо растворимым фармакологическим веществом является паклитаксел.
24. Способ лечения рака у индивидуума, включающий введение субъекту эффективного количества композиции по пп.1-12, где слабо растворимым фармакологическим веществом является антинеопластическое вещество.
25. Способ по п.24, где количество противомикробного вещества в композиции не вызывает токсического эффекта, когда композицию вводят индивидууму.
26. Способ консервирования композиции, содержащей слабо растворимое в воде фармацевтическое вещество и белок-носитель, от значимого микробного роста, включающий добавление к композиции противомикробного вещества, отличного от дефероксамина, в количестве, которое эффективно подавляет микробный рост в композиции.
27. Сухая композиция, содержащая слабо растворимое фармацевтическое вещество, белок-носитель и сахар, где композицию можно восстановить в стабильную водную суспензию слабо растворимого фармацевтического вещества и где время восстановления композиции меньше чем для композиции без сахара, где концентрация сахара в восстановленной суспензии выше чем приблизительно 50 мг/мл.
28. Композиция по п.27, дополнительно содержащая противомикробное вещество, где подавлен значимый рост микробов в композиции.
29. Композиция по п.27, где сахаром является сукроза или маннит.
30. Композиция по п.27, где слабо растворимым в воде фармацевтическим веществом является паклитаксел.
31. Композиция по п.27, где белком-носителем является альбумин.
32. Композиция, содержащая паклитаксел, альбумин и сахар, где весовое отношение альбумина к паклитакселу составляет приблизительно 9:1 или менее, и где концентрация сахара в композиции или восстановленной из композиции суспензии выше чем приблизительно 50 мг/мл.
33. Композиция по п.32, где композиция содержит наночастицы, содержащие альбумин и паклитаксел.
34. Композиция по п.32 или 33, где сахаром является сукроза или маннит.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71286505P | 2005-08-31 | 2005-08-31 | |
US60/712,865 | 2005-08-31 | ||
US73693105P | 2005-11-14 | 2005-11-14 | |
US73696205P | 2005-11-14 | 2005-11-14 | |
US60/736,931 | 2005-11-14 | ||
US60/736,962 | 2005-11-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2008112144A true RU2008112144A (ru) | 2009-10-10 |
RU2433818C2 RU2433818C2 (ru) | 2011-11-20 |
Family
ID=37700819
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008112144A RU2433818C2 (ru) | 2005-08-31 | 2006-08-30 | Композиции, включающие слаборастворимые в воде фармацевтические вещества и противомикробные вещества |
RU2008112146/15A RU2451510C2 (ru) | 2005-08-31 | 2006-08-30 | Композиции и способы получения слаборастворимых в воде лекарственных средств с увеличенной стабильностью |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008112146/15A RU2451510C2 (ru) | 2005-08-31 | 2006-08-30 | Композиции и способы получения слаборастворимых в воде лекарственных средств с увеличенной стабильностью |
Country Status (25)
Country | Link |
---|---|
US (7) | US7771751B2 (ru) |
EP (5) | EP2399573B1 (ru) |
JP (2) | JP5461837B2 (ru) |
KR (1) | KR101420445B1 (ru) |
CN (3) | CN104189905A (ru) |
AU (1) | AU2006284808B2 (ru) |
BR (1) | BRPI0615265A8 (ru) |
CA (3) | CA2848021C (ru) |
CY (2) | CY1121461T1 (ru) |
DK (2) | DK3311805T3 (ru) |
ES (4) | ES2718323T3 (ru) |
HK (1) | HK1252388A1 (ru) |
HU (2) | HUE042678T2 (ru) |
IL (3) | IL189601A (ru) |
LT (2) | LT3311805T (ru) |
NO (2) | NO345390B1 (ru) |
NZ (1) | NZ566696A (ru) |
PL (2) | PL3311805T3 (ru) |
PT (2) | PT3311805T (ru) |
RU (2) | RU2433818C2 (ru) |
SI (2) | SI3311805T1 (ru) |
TR (2) | TR200801337T1 (ru) |
TW (2) | TWI417114B (ru) |
WO (1) | WO2007027819A2 (ru) |
ZA (1) | ZA200802765B (ru) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070122465A1 (en) * | 1993-02-22 | 2007-05-31 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
CN100462066C (zh) * | 1997-06-27 | 2009-02-18 | 美国生物科学有限公司 | 药剂的新制剂及其制备和应用方法 |
EP2359859A1 (en) | 2002-12-09 | 2011-08-24 | Abraxis BioScience, LLC | Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents |
AU2012201568B2 (en) * | 2005-02-18 | 2014-07-31 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
CA3054535A1 (en) * | 2005-02-18 | 2006-08-24 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
US7771751B2 (en) * | 2005-08-31 | 2010-08-10 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
EP3527202A1 (en) | 2005-08-31 | 2019-08-21 | Abraxis BioScience, LLC | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
ES2700074T3 (es) | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano |
RU2483714C2 (ru) * | 2007-03-07 | 2013-06-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи. | Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента |
CA2686736A1 (en) * | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension |
US8927019B2 (en) * | 2007-06-01 | 2015-01-06 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
CA2721153C (en) * | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
CN102026667B (zh) * | 2008-04-18 | 2014-06-25 | 安吉奥开米公司 | 紫杉醇、紫杉醇类似物或紫杉醇结合物的药物组合物及相关制备方法和用途 |
EP2201935B1 (en) * | 2008-12-26 | 2020-07-08 | Samyang Biopharmaceuticals Corporation | Polymeric micelle composition containing a poorly soluble drug and preparation method of the same |
RS59896B1 (sr) * | 2009-04-15 | 2020-03-31 | Abraxis Bioscience Llc | Kompozicije nanočestica bez priona i postupci povezani sa njima |
US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
US20110155620A1 (en) * | 2009-12-30 | 2011-06-30 | Baxter International Inc. | Rapid reconstitution for lyophilized-pharmaceutical suspensions |
WO2011104557A1 (en) * | 2010-02-24 | 2011-09-01 | Arecor Limited | Protein formulations |
CA2793536C (en) * | 2010-03-26 | 2019-10-01 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
MX2012011155A (es) | 2010-03-29 | 2012-12-05 | Abraxis Bioscience Llc | Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos. |
HUE030207T2 (en) | 2010-03-29 | 2017-04-28 | Abraxis Bioscience Llc | Cancer Treatment Procedures |
WO2011135580A2 (en) * | 2010-04-28 | 2011-11-03 | Cadila Healthcare Limited | Pharmaceutical compositions of sirolimus |
ES2652509T3 (es) | 2010-05-03 | 2018-02-02 | Teikoku Pharma Usa, Inc. | Formulaciones de proemulsión de taxano no acuosas y métodos para la preparación y el uso de las mismas |
AU2011261685B2 (en) | 2010-06-04 | 2016-02-11 | Abraxis Bioscience, Llc | Methods of treatment of pancreatic cancer |
LT2694056T (lt) | 2011-04-01 | 2019-12-10 | Astrazeneca Ab | Terapinis gydymas |
SG10201606406PA (en) | 2011-04-28 | 2016-09-29 | Abraxis Bioscience Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
US9427477B2 (en) | 2011-05-09 | 2016-08-30 | Mayo Foundation For Medical Education And Research | Cancer treatments |
MX2014005314A (es) | 2011-11-01 | 2014-09-08 | Celgene Corp | Metodos para tratar canceres utilizando formulaciones orales de analogos de citidina. |
GB201119173D0 (en) * | 2011-11-07 | 2011-12-21 | Fujifilm Mfg Europe Bv | Porous tissue scaffolds |
JP6309454B2 (ja) | 2011-11-30 | 2018-04-11 | アストラゼネカ アクチボラグ | 癌の併用処置 |
RU2705998C2 (ru) | 2011-12-14 | 2019-11-13 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Применение полимерных эксципиентов для лиофилизации или заморозки частиц |
LT2833905T (lt) | 2012-04-04 | 2018-07-10 | Halozyme, Inc. | Derinių terapija su hialuronidaze ir į naviką nukreiptu taksanu |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
EP2903610B1 (en) | 2012-10-01 | 2021-11-03 | Mayo Foundation For Medical Education And Research | Cancer treatments |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
CN105142629B (zh) | 2013-03-04 | 2018-11-23 | 阿斯利康(瑞典)有限公司 | 组合治疗 |
CN110279864A (zh) | 2013-03-12 | 2019-09-27 | 阿布拉科斯生物科学有限公司 | 治疗肺癌的方法 |
NZ630213A (en) | 2013-03-14 | 2017-05-26 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
CN103734153B (zh) * | 2014-01-20 | 2016-04-27 | 王德昌 | 一种含活性阿维菌素的水溶性生物杀虫剂及其制备方法 |
KR20210125603A (ko) | 2014-06-16 | 2021-10-18 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 골수종의 치료 |
WO2015195634A1 (en) | 2014-06-17 | 2015-12-23 | Celgne Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
CN106137969B (zh) * | 2015-04-03 | 2020-05-15 | 四川科伦药物研究院有限公司 | 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用 |
EP3313401B1 (en) | 2015-06-29 | 2021-10-06 | Abraxis BioScience, LLC | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體-抗體組合物及其製造及使用方法 |
TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
EP3399861A4 (en) | 2016-01-07 | 2019-08-07 | Mayo Foundation for Medical Education and Research | INTERFERON CANCER TREATMENT METHODS |
WO2017139698A1 (en) | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
US11585805B2 (en) | 2016-02-19 | 2023-02-21 | Nantcell, Inc. | Methods of immunogenic modulation |
CA3018340A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
EP3432926A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | METHODS OF REDUCING THE TOXICITY OF A CHEMOTHERAPEUTIC MEDICAMENT |
CN109563521A (zh) | 2016-03-24 | 2019-04-02 | 河谷细胞有限公司 | 用于新表位呈递的序列排列和序列 |
US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
TW201803598A (zh) | 2016-06-30 | 2018-02-01 | 南特細胞公司 | Nant癌症疫苗 |
KR102462041B1 (ko) | 2016-09-01 | 2022-11-02 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 암 치료용 담체-pd-l1 결합제 조성물 |
US11160876B2 (en) | 2016-09-01 | 2021-11-02 | Mayo Foundation For Medical Education And Research | Methods and compositions for targeting t-cell cancers |
US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
RU2021128415A (ru) * | 2016-09-06 | 2021-11-08 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения |
RU2019110071A (ru) | 2016-09-06 | 2020-10-08 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Способы лечения злокачественных новообразований, экспрессирующих pd-l1 |
US11564944B2 (en) | 2016-11-21 | 2023-01-31 | Nant Holdings Ip, Llc | Fractal combination therapy |
US11229668B2 (en) | 2017-02-07 | 2022-01-25 | Nantcell, Inc. | Maximizing T-cell memory and compositions and methods therefor |
CA3061240C (en) | 2017-04-24 | 2024-01-16 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
WO2019090098A1 (en) * | 2017-11-03 | 2019-05-09 | Emerald Kalama Chemical, Llc | Boosters for antimicrobial, preservative and biocidal applications |
IL274444B1 (en) | 2017-11-06 | 2024-02-01 | Rapt Therapeutics Inc | Chemokine receptor modulators for the treatment of Epstein-Barr virus-positive cancer |
CN107970210A (zh) * | 2017-12-05 | 2018-05-01 | 湖北九州通中加医药有限公司 | 一种非预溶性多西他赛注射液 |
US11773187B2 (en) | 2018-01-17 | 2023-10-03 | Nantbio, Inc. | Enhanced immunogenicity for GPI-anchored antigens |
WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
MX2020009740A (es) | 2018-03-20 | 2021-01-20 | Abraxis Bioscience Llc | Metodos para el tratamiento de trastornos del sistema nervioso central mediante la administracion de nanoparticulas de un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y una albumina. |
US20210023041A1 (en) * | 2018-04-11 | 2021-01-28 | Zhuhai Beihai Biotech Co., Ltd. | Formulations and compositions of docetaxel |
US11823773B2 (en) | 2018-04-13 | 2023-11-21 | Nant Holdings Ip, Llc | Nant cancer vaccine strategies |
US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
US11413275B1 (en) | 2018-12-14 | 2022-08-16 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
US10478422B1 (en) | 2018-12-14 | 2019-11-19 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
US11446243B1 (en) * | 2019-08-05 | 2022-09-20 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
MX2022004989A (es) | 2019-10-28 | 2022-07-21 | Abraxis Bioscience Llc | Composiciones farmaceuticas de albumina y rapamicina. |
KR20220137019A (ko) * | 2020-02-04 | 2022-10-11 | 주하이 베이하이 바이오테크 컴퍼니 리미티드 | 도세탁셀의 제형 |
KR20230154864A (ko) | 2021-03-05 | 2023-11-09 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | 안정한 도세탁셀 알부민 나노입자 조성물 |
KR102576559B1 (ko) * | 2021-06-14 | 2023-09-08 | 충북대학교 산학협력단 | 도세탁셀 및 아파티닙이 봉입된 알부민 나노입자 및 이의 용도 |
WO2023076425A1 (en) * | 2021-10-26 | 2023-05-04 | Ecs Brands, Ltd. | Albumin protein for use as an emulsifier and drug carrier |
WO2023154902A1 (en) * | 2022-02-11 | 2023-08-17 | Sameer Sabir | Compositions of and methods for a cold slurry having hyaluronic acid |
WO2023194441A1 (en) | 2022-04-05 | 2023-10-12 | Istituto Nazionale Tumori Irccs - Fondazione G. Pascale | Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer |
Family Cites Families (175)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
FR2601675B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR2608988B1 (fr) | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
US5334582A (en) | 1988-06-22 | 1994-08-02 | Applied Microbiology, Inc. | Pharmaceutical bacteriocin compositions and methods for using the same |
US4960799A (en) | 1988-09-13 | 1990-10-02 | Ciba-Geigy Corporation | Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use |
US6018031A (en) | 1989-10-20 | 2000-01-25 | Trustees Of Dartmouth College | Binding agents specific for IgA receptor |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US6120805A (en) * | 1990-04-06 | 2000-09-19 | Rhone-Poulenc Rorer Sa | Microspheres, process for their preparation and their use |
US5725804A (en) | 1991-01-15 | 1998-03-10 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU5553894A (en) | 1992-11-27 | 1994-06-22 | F.H. Faulding & Co. Limited | Injectable taxol composition |
DK0835657T3 (da) | 1992-11-27 | 2005-01-10 | Mayne Pharma Usa Inc | Stabil, injicerbar paclitaxelsammensætning |
US6410374B1 (en) * | 1992-12-26 | 2002-06-25 | Semiconductor Energy Laborartory Co., Ltd. | Method of crystallizing a semiconductor layer in a MIS transistor |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
US20030073642A1 (en) | 1993-02-22 | 2003-04-17 | American Bioscience, Inc. | Methods and formulations for delivery of pharmacologically active agents |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US20030133955A1 (en) | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US20070122465A1 (en) | 1993-02-22 | 2007-05-31 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
US6528067B1 (en) * | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
JP3746293B2 (ja) | 1993-02-22 | 2006-02-15 | アメリカン バイオサイエンス、インコーポレイテッド | 生物製剤のインビボ送達の方法とそのための組成物 |
US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
EP2226085B1 (en) | 1993-07-19 | 2013-11-27 | Angiotech Pharmaceuticals, Inc. | Anti-angiogenic compositions and methods of use |
GB9405593D0 (en) | 1994-03-22 | 1994-05-11 | Zeneca Ltd | Pharmaceutical compositions |
US5731355A (en) | 1994-03-22 | 1998-03-24 | Zeneca Limited | Pharmaceutical compositions of propofol and edetate |
FR2722191B1 (fr) | 1994-07-08 | 1996-08-23 | Rhone Poulenc Rorer Sa | Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle |
DE4438577A1 (de) | 1994-10-28 | 1996-05-02 | Basf Ag | Selbsttragende Dübelmasse für die chemische Befestigungstechnik |
US5681846A (en) | 1995-03-17 | 1997-10-28 | Board Of Regents, The University Of Texas System | Extended stability formulations for paclitaxel |
US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
US6964947B1 (en) | 1995-11-07 | 2005-11-15 | Genentech, Inc. | Stabilizing formulation for NGF |
US6537539B2 (en) | 1996-01-11 | 2003-03-25 | Human Genome Sciences, Inc. | Immune cell cytokine |
CZ297979B6 (cs) * | 1996-03-12 | 2007-05-16 | Pg-Txl Company, L. P. | Kompozice obsahující protinádorové lécivo konjugované s ve vode rozpustným polymerem, její pouzití pro výrobu léciva a implantovatelná lékarská pomucka |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US5637625A (en) | 1996-03-19 | 1997-06-10 | Research Triangle Pharmaceuticals Ltd. | Propofol microdroplet formulations |
KR100330373B1 (ko) | 1996-05-28 | 2002-11-07 | 주식회사한국신약 | 탁솔을 함유한 주사용 약제 조성물 |
GB9613182D0 (en) | 1996-06-24 | 1996-08-28 | Nycomed Imaging As | Method |
US5731556A (en) | 1996-09-30 | 1998-03-24 | Ingersoll-Rand Company | Muffler for pneumatic device |
US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
TR199903123T2 (xx) | 1997-04-07 | 2000-05-22 | Genentech, Inc. | Anti-Vegf antikorlar�. |
US20050019266A1 (en) | 1997-05-06 | 2005-01-27 | Unger Evan C. | Novel targeted compositions for diagnostic and therapeutic use |
US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
US20020039594A1 (en) | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
CH692322A5 (it) | 1997-05-26 | 2002-05-15 | Westy Ag | Formulazione iniettabile limpida di Propofol. |
US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
CN100462066C (zh) | 1997-06-27 | 2009-02-18 | 美国生物科学有限公司 | 药剂的新制剂及其制备和应用方法 |
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US6217886B1 (en) | 1997-07-14 | 2001-04-17 | The Board Of Trustees Of The University Of Illinois | Materials and methods for making improved micelle compositions |
TR199901008T1 (xx) | 1997-09-09 | 2000-02-21 | Select Release, L.C. | Kaplanm�� partik�ller, yap�m� ve kullan�m y�ntemleri. |
US5925776A (en) | 1997-12-24 | 1999-07-20 | Schein Pharmacetical, Inc. | Polyethoxylated castor oil, process of making the same and formulations thereof |
AR015516A1 (es) | 1998-02-10 | 2001-05-02 | Gensia Sicor Inc | Composicion farmaceutica esteril para administracion parenteral y uso de la misma para preparar un medicamento |
PL202536B1 (pl) | 1998-02-27 | 2009-07-31 | Straumann Inst Ag | Zastosowanie preparatu aktywnej substancji szkliwa |
US6914130B2 (en) | 1998-06-17 | 2005-07-05 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO2000006152A1 (en) * | 1998-07-30 | 2000-02-10 | Novopharm Biotech, Inc. | Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin |
AU759641B2 (en) | 1998-08-19 | 2003-04-17 | Skyepharma Canada Inc. | Injectable aqueous dispersions of propofol |
US6150423A (en) | 1998-10-15 | 2000-11-21 | Phoenix Scientific, Inc. | Propofol-based anesthetic and method of making same |
US6028108A (en) * | 1998-10-22 | 2000-02-22 | America Home Products Corporation | Propofol composition comprising pentetate |
US6140374A (en) | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
US6140373A (en) | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
DE19856432A1 (de) * | 1998-12-08 | 2000-06-15 | Basf Ag | Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen |
ES2226203T3 (es) | 1998-12-23 | 2005-03-16 | Idea Ag | Formulacion mejorada para aplicacion topica no invasiva. |
WO2000040269A2 (en) | 1999-01-05 | 2000-07-13 | Lee Clarence C | Pharmaceutical compositions for treatment of diseased tissues |
PT1143962E (pt) | 1999-01-28 | 2005-03-31 | Kurani Shashikant Prabhudas | Solucao parenterica de propofol (2,6-di-isopropilfenol) e 2,5-di-o-metil-1,4;3,6-di-anidro-d-glucitol, como dissolvente |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6177477B1 (en) | 1999-03-24 | 2001-01-23 | American Home Products Corporation | Propofol formulation containing TRIS |
EP1165046A1 (en) | 1999-04-05 | 2002-01-02 | Baxter International Inc. | Propofol compositions containing preservative additives |
US6100302A (en) | 1999-04-05 | 2000-08-08 | Baxter International Inc. | Propofol formulation with enhanced microbial characteristics |
CA2369740A1 (en) | 1999-04-22 | 2000-11-02 | American Biosciences, Inc. | Long term administration of pharmacologically active agents |
EP1178786A4 (en) * | 1999-05-21 | 2006-03-01 | American Bioscience Inc | PHARMACOLOGICALLY ACTIVE PROTEIN STABILIZING AGENTS; METHODS OF MANUFACTURE AND METHODS OF USE |
US6610317B2 (en) | 1999-05-27 | 2003-08-26 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
CA2377614C (en) | 1999-06-21 | 2008-07-29 | Kuhnil Pharm. Co., Ltd. | Anesthetic composition for intravenous injection comprising propofol |
GB9920548D0 (en) | 1999-08-31 | 1999-11-03 | Rhone Poulenc Rorer Sa | Treatment of hepatocellular carcinoma |
DE60025503T2 (de) * | 1999-09-17 | 2006-09-07 | Daiichi Asubio Pharma Co., Ltd. | Pharmazeutische Zusammensetzungen, die Faropenem-Natrium und eine Diaminoacetat Verbindung zur Verbesserung der Magen-Darm-Trakt Absorption enthalten |
JP4601100B2 (ja) * | 1999-11-08 | 2010-12-22 | 三生医薬株式会社 | マスティックの油液を内包した軟カプセル |
JP2003520210A (ja) * | 2000-01-05 | 2003-07-02 | イマレックス セラピューティクス, インコーポレイテッド | 低い水溶性を有する薬物の送達のための薬学的処方物 |
AR027714A1 (es) | 2000-03-24 | 2003-04-09 | Baker Norton Pharma | Uso de sales metalicas para estabilizar composiciones de taxanos. |
ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
AU6689601A (en) | 2000-06-16 | 2002-01-02 | Rtp Pharma Inc | Improved injectable dispersions of propofol |
AU2001270310A1 (en) | 2000-07-07 | 2002-01-21 | Guilford Pharmaceuticals Inc. | Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same |
DE10036871A1 (de) | 2000-07-28 | 2002-02-14 | Pharmasol Gmbh | Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe |
US6623765B1 (en) | 2000-08-01 | 2003-09-23 | University Of Florida, Research Foundation, Incorporated | Microemulsion and micelle systems for solubilizing drugs |
US6881731B1 (en) | 2000-10-23 | 2005-04-19 | Shanbrom Technologies, Llc | Enhancers for microbiological disinfection |
EP1337273A2 (en) | 2000-11-28 | 2003-08-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
US20040033273A1 (en) | 2001-02-14 | 2004-02-19 | Ayurcore, Inc. | Withasol and methods of use |
US20030157161A1 (en) | 2001-05-01 | 2003-08-21 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents |
WO2003007914A2 (en) * | 2001-07-19 | 2003-01-30 | Guilford Pharmaceuticals, Inc. | Biocompatible polymer containing composition for treatment of prostate cancers |
US6962944B2 (en) * | 2001-07-31 | 2005-11-08 | Arqule, Inc. | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
US20030099674A1 (en) | 2001-08-11 | 2003-05-29 | Chen Andrew X. | Lyophilized injectable formulations containing paclitaxel or other taxoid drugs |
US6680330B2 (en) * | 2001-08-22 | 2004-01-20 | Wyeth | Rapamycin dialdehydes |
GB0120702D0 (en) | 2001-08-24 | 2001-10-17 | Maelor Pharmaceuticals Ltd | Anaesthetic formulations |
KR100774366B1 (ko) | 2001-09-10 | 2007-11-08 | 주식회사 중외제약 | 파클리탁셀 주사제 조성물 |
US7112340B2 (en) | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
HUP0500843A2 (hu) | 2001-12-20 | 2005-12-28 | Bristol-Myers Squibb Co., | Fokozott biológiai hasznosulású, szájon át hatásos taxánszármazékokat tartalmazó gyógyszerkészítmények |
US20040210289A1 (en) | 2002-03-04 | 2004-10-21 | Xingwu Wang | Novel nanomagnetic particles |
US20040143004A1 (en) | 2002-02-26 | 2004-07-22 | Joseph Fargnoli | Metronomic dosing of taxanes |
ITMI20020681A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
CN1448132A (zh) | 2002-03-29 | 2003-10-15 | 艾斯·多伯法股份公司 | 改进的基于紫杉醇的抗肿瘤制剂 |
ITMI20020680A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
US20040009168A1 (en) | 2002-04-05 | 2004-01-15 | Elizabet Kaisheva | Multidose antibody formulation |
SI21222A (sl) * | 2002-05-28 | 2003-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Postopek za pripravo nanodelcev |
EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
CN1694689A (zh) | 2002-09-30 | 2005-11-09 | 阿库斯菲尔公司 | 供吸入的缓释多孔微粒 |
US20040126360A1 (en) | 2002-10-09 | 2004-07-01 | Manning Mark C. | Oral formulations for proteins and polypeptides |
EP1585504A4 (en) * | 2002-11-06 | 2009-07-15 | Azaya Therapeutics Inc | LIPOSOMAL PREPARATIONS OF PHARMACEUTICAL AGENTS STABILIZED BY PROTEINS |
EP2359859A1 (en) | 2002-12-09 | 2011-08-24 | Abraxis BioScience, LLC | Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents |
NZ541142A (en) | 2002-12-09 | 2008-07-31 | Abraxis Bioscience Inc | Compositions and methods of delivery of pharmacological agents |
US6838569B2 (en) | 2002-12-16 | 2005-01-04 | Dabur India Limited | Process for preparation of paclitaxel trihydrate and docetaxel trihydrate |
US20040171560A1 (en) | 2002-12-23 | 2004-09-02 | Dabur Research Foundation | Stabilized pharmaceutical composition |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
US6900184B2 (en) | 2003-04-14 | 2005-05-31 | Wyeth Holdings Corporation | Compositions containing pipercillin and tazobactam useful for injection |
CN1268619C (zh) | 2003-05-08 | 2006-08-09 | 上海迪赛诺化学制药有限公司 | 多烯紫杉醇三水化合物的制备方法 |
RU2005136988A (ru) | 2003-05-30 | 2006-06-10 | Дженентек, Инк. (Us) | Лечение антителами против vegf |
US20040247624A1 (en) * | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
EP1643969A2 (en) * | 2003-07-11 | 2006-04-12 | Pro-Pharmaceuticals, Inc. | Compositions and methods for hydrophobic drug delivery |
US20050152979A1 (en) | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
ZA200603619B (en) | 2003-11-06 | 2008-10-29 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
WO2005052116A2 (en) | 2003-11-19 | 2005-06-09 | Merck & Co., Inc. | Preservative-containing virus formulations |
WO2005051451A2 (en) | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Electrical devices and anti-scarring agents |
US7012223B2 (en) | 2003-11-25 | 2006-03-14 | National Environmental Products, Ltd. | Forced-air heater control system and method |
WO2005061474A1 (en) | 2003-12-12 | 2005-07-07 | Quiral Química Do Brasil | Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions |
WO2005062992A2 (en) * | 2003-12-23 | 2005-07-14 | Abraxis Bioscience, Inc | Substituted melatonin derivatives, process for their preparation, and methods of use |
JP2005225818A (ja) * | 2004-02-13 | 2005-08-25 | Otsuka Pharmaceut Factory Inc | パクリタキセル又はドセタキセルの医薬組成物 |
KR20050099311A (ko) | 2004-04-09 | 2005-10-13 | 에이엔에이치 케어연구소(주) | 주사제용 항암제 조성물 |
US8420603B2 (en) | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
US20060079672A1 (en) | 2004-10-07 | 2006-04-13 | Paul Glidden | Kits for modulating angiogenesis |
US8557861B2 (en) * | 2004-09-28 | 2013-10-15 | Mast Therapeutics, Inc. | Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
JP5243041B2 (ja) | 2004-12-21 | 2013-07-24 | ネクター セラピューティックス | 安定化ポリマーチオール試薬 |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
EP1869077A2 (en) | 2005-02-18 | 2007-12-26 | Abraxis BioScience, Inc. | Q3 sparc deletion mutant and uses thereof |
CA3054535A1 (en) | 2005-02-18 | 2006-08-24 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
BRPI0608173A2 (pt) * | 2005-02-24 | 2010-11-09 | Elan Pharma Int Ltd | composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo |
EP1862183B1 (en) | 2005-03-14 | 2010-11-03 | Otsuka Pharmaceutical Factory, Inc. | Kit comprising drug and fat emulsion |
WO2006133510A1 (en) | 2005-06-17 | 2006-12-21 | Hospira Australia Pty Ltd | Liquid pharmaceutical formulations of docetaxel |
US20070025910A1 (en) | 2005-07-29 | 2007-02-01 | Norenberg Jeffrey P | Anticancer therapy |
EP3527202A1 (en) | 2005-08-31 | 2019-08-21 | Abraxis BioScience, LLC | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
US7771751B2 (en) | 2005-08-31 | 2010-08-10 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
JP2008523111A (ja) | 2005-10-12 | 2008-07-03 | シコール インコーポレイティド | ドセタキセルの結晶形及びそれらの調製方法 |
CA2642324C (en) | 2006-02-21 | 2011-03-29 | Dabur Pharma Limited | Stable pharmaceutical composition of taxanes |
US20100160653A1 (en) | 2006-03-21 | 2010-06-24 | Dr. Reddy's Laboratories Ltd. | Docetaxel polymorphs and processes |
CN101568332A (zh) | 2006-08-31 | 2009-10-28 | 阿布拉科斯生物科学公司 | 抑制血管生成及治疗血管生成相关疾病的方法 |
US20080280987A1 (en) | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
ES2700074T3 (es) * | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano |
RU2483714C2 (ru) | 2007-03-07 | 2013-06-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи. | Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента |
CA2686736A1 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension |
US8927019B2 (en) | 2007-06-01 | 2015-01-06 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
JP2011517683A (ja) | 2008-04-10 | 2011-06-16 | アブラクシス バイオサイエンス, エルエルシー | 疎水性タキサン誘導体の組成物およびその使用 |
CA2721153C (en) | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
WO2010068925A1 (en) * | 2008-12-11 | 2010-06-17 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
BRPI1008955A2 (pt) | 2009-03-13 | 2015-09-01 | Abraxis Bioscience Llc | Terapia de combinação com derivados de tiocolchicina. |
JP2012523433A (ja) | 2009-04-10 | 2012-10-04 | アブラクシス バイオサイエンス, エルエルシー | ナノ粒子処方物およびその使用 |
RS59896B1 (sr) | 2009-04-15 | 2020-03-31 | Abraxis Bioscience Llc | Kompozicije nanočestica bez priona i postupci povezani sa njima |
RU2561055C2 (ru) * | 2009-08-25 | 2015-08-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог |
CA2793536C (en) * | 2010-03-26 | 2019-10-01 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
MX2012011155A (es) * | 2010-03-29 | 2012-12-05 | Abraxis Bioscience Llc | Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos. |
HUE030207T2 (en) * | 2010-03-29 | 2017-04-28 | Abraxis Bioscience Llc | Cancer Treatment Procedures |
CA2801314A1 (en) * | 2010-06-02 | 2011-12-08 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
AU2011261685B2 (en) * | 2010-06-04 | 2016-02-11 | Abraxis Bioscience, Llc | Methods of treatment of pancreatic cancer |
AU2011264590B2 (en) | 2010-06-07 | 2016-12-15 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
SG10201606406PA (en) | 2011-04-28 | 2016-09-29 | Abraxis Bioscience Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
-
2006
- 2006-08-30 US US11/514,030 patent/US7771751B2/en active Active
- 2006-08-30 NO NO20191301A patent/NO345390B1/no unknown
- 2006-08-30 WO PCT/US2006/033931 patent/WO2007027819A2/en active Application Filing
- 2006-08-30 RU RU2008112144A patent/RU2433818C2/ru active
- 2006-08-30 DK DK17202081.0T patent/DK3311805T3/da active
- 2006-08-30 RU RU2008112146/15A patent/RU2451510C2/ru active
- 2006-08-30 ES ES11169998T patent/ES2718323T3/es active Active
- 2006-08-30 SI SI200632373T patent/SI3311805T1/sl unknown
- 2006-08-30 PT PT172020810T patent/PT3311805T/pt unknown
- 2006-08-30 HU HUE06813980A patent/HUE042678T2/hu unknown
- 2006-08-30 BR BRPI0615265A patent/BRPI0615265A8/pt not_active Application Discontinuation
- 2006-08-30 CN CN201410319045.5A patent/CN104189905A/zh active Pending
- 2006-08-30 ES ES06813980T patent/ES2720603T3/es active Active
- 2006-08-30 EP EP11169998.9A patent/EP2399573B1/en active Active
- 2006-08-30 ES ES17202081T patent/ES2784794T3/es active Active
- 2006-08-30 KR KR1020087007604A patent/KR101420445B1/ko active IP Right Grant
- 2006-08-30 EP EP20151407.2A patent/EP3659589A1/en not_active Withdrawn
- 2006-08-30 EP EP17202081.0A patent/EP3311805B1/en active Active
- 2006-08-30 CN CNA2006800387713A patent/CN101291659A/zh active Pending
- 2006-08-30 TW TW95132027A patent/TWI417114B/zh active
- 2006-08-30 TW TW95132009A patent/TWI429452B/zh active
- 2006-08-30 AU AU2006284808A patent/AU2006284808B2/en active Active
- 2006-08-30 CN CN201210585716.3A patent/CN103054798B/zh active Active
- 2006-08-30 LT LTEP17202081.0T patent/LT3311805T/lt unknown
- 2006-08-30 TR TR200801337T patent/TR200801337T1/xx unknown
- 2006-08-30 HU HUE17202081A patent/HUE048521T2/hu unknown
- 2006-08-30 ES ES11170007.6T patent/ES2663324T3/es active Active
- 2006-08-30 CA CA2848021A patent/CA2848021C/en active Active
- 2006-08-30 DK DK06813980.7T patent/DK1931321T3/en active
- 2006-08-30 NZ NZ566696A patent/NZ566696A/en unknown
- 2006-08-30 JP JP2008529249A patent/JP5461837B2/ja active Active
- 2006-08-30 PT PT06813980T patent/PT1931321T/pt unknown
- 2006-08-30 PL PL17202081T patent/PL3311805T3/pl unknown
- 2006-08-30 CA CA2880727A patent/CA2880727C/en active Active
- 2006-08-30 CA CA2620585A patent/CA2620585C/en active Active
- 2006-08-30 SI SI200632324T patent/SI1931321T1/sl unknown
- 2006-08-30 EP EP06813980.7A patent/EP1931321B1/en active Active
- 2006-08-30 PL PL06813980T patent/PL1931321T3/pl unknown
- 2006-08-30 LT LTEP06813980.7T patent/LT1931321T/lt unknown
- 2006-08-30 ZA ZA200802765A patent/ZA200802765B/xx unknown
- 2006-08-30 TR TR200801336T patent/TR200801336T1/xx unknown
- 2006-08-30 EP EP11170007.6A patent/EP2404594B1/en active Active
-
2008
- 2008-02-19 IL IL189601A patent/IL189601A/en active IP Right Grant
- 2008-03-28 NO NO20081543A patent/NO343593B1/no unknown
-
2010
- 2010-06-17 US US12/818,099 patent/US20110118342A1/en not_active Abandoned
- 2010-06-25 US US12/824,014 patent/US20110151012A1/en not_active Abandoned
- 2010-09-02 US US12/874,965 patent/US20110196026A1/en not_active Abandoned
-
2012
- 2012-02-29 US US13/408,994 patent/US9308180B2/en active Active
-
2013
- 2013-07-22 JP JP2013151445A patent/JP2013213069A/ja not_active Withdrawn
-
2016
- 2016-04-17 IL IL245152A patent/IL245152B/en active IP Right Grant
- 2016-06-09 US US15/178,469 patent/US20170007569A1/en not_active Abandoned
-
2018
- 2018-09-12 HK HK18111685.7A patent/HK1252388A1/zh unknown
-
2019
- 2019-02-22 US US16/283,469 patent/US20190343789A1/en not_active Abandoned
- 2019-03-26 CY CY20191100347T patent/CY1121461T1/el unknown
-
2020
- 2020-01-26 IL IL272235A patent/IL272235A/en unknown
- 2020-04-08 CY CY20201100334T patent/CY1123047T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2008112144A (ru) | Композиции, включающие слаборастворимые в воде фармацевтические вещества и противомикробные вещества | |
JP2009506126A5 (ru) | ||
KR101502533B1 (ko) | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 | |
KR100718760B1 (ko) | 로티고틴의 비내 제형 | |
US20090221688A1 (en) | Pharmaceutical compositions containing docetaxel and a degradation inhibitor and a process for obtaining the same | |
RU2013112353A (ru) | Фосфолипидный депо-препарат | |
PL199652B1 (pl) | Sposób wytwarzania stałych kompozycji farmaceutycznych | |
JP2009538294A (ja) | 安定性を有するドセタキセル含有医薬組成物、及びその製造方法 | |
JP2018530606A5 (ru) | ||
AU2005223618A1 (en) | Tissue detoxification and health supplements and methods of making and using them | |
SI2231189T1 (en) | A delivery system for administering pharmaceutical active substances that are poorly soluble in water | |
CN103751107A (zh) | 含有多烯紫杉醇和维生素e tpgs的纳米颗粒及其制备方法 | |
CN108464969B (zh) | 非水紫杉烷纳米分散制剂及其使用方法 | |
AU2002351169B2 (en) | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions | |
CN1565430A (zh) | 大蒜素环糊精包合物、制剂及制备方法 | |
CN1282458C (zh) | 头孢羟氨苄干混悬及制备方法 | |
US20060134244A1 (en) | Breast health supplement and detoxification preparations | |
WO1999030728A1 (fr) | Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation | |
CZ2005796A3 (cs) | Farmaceutická kompozice obsahující derivát taxanuse zlepsenou terapeutickou úcinností | |
CN111465389B (zh) | 多西他赛共缀物的药物组合物及制备方法 | |
CN104645334B (zh) | N‑乙酰半胱氨酸活性炭组合物及其制备方法和应用 | |
CN107550887B (zh) | 一种治疗t细胞急性淋巴细胞白血病的复方纳米制剂及制备方法和应用 | |
PL203300B1 (pl) | Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego | |
JPH09165345A (ja) | ギンコリド属からの血小板抗凝集剤を溶解するための天然シクロデキストリンおよびその誘導体の使用 | |
CN101292959A (zh) | 一种黄豆苷元粉针剂及其制备方法 |